ArticleThe Indian journal of medical research2025
Evaluation of the rapid lateral flow assay (LFA) for detection of five major carbapenemase enzyme families in genotypically characterised bacterial isolates.
Article in The Indian journal of medical research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Direct-from-Specimen Detection of Major Carbapenemases by Carbapenem-Resistant K.N.I.V.O. Detection K-Set: Comparative Analysis of Accuracy and Turnaround Time.Pathogens (Basel, Switzerland) · 2026Article
- Evaluation of Beta-Lactamase-Producing Strains Isolated in a Tertiary Nephrology Hospital in Romania.Antibiotics (Basel, Switzerland) · 2026Article
- The evolution of next-generation lateral flow assays for bacterial and fungal diagnostics.Mikrochimica acta · 2026Review
- Development and Evaluation of a Duplex Lateral Flow Immunoassay for Rapid Detection of KPC and NDM Carbapenemases.Infection and drug resistance · 2026Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Background & objectives Antimicrobial resistance has steadily become a grave public health problem worldwide, making carbapenems, often the last choice of antibiotic, for treating infections involving multidrug-resistant Gram-negative organisms. The production of carbapenemases is one of the primary mechanisms responsible for the development of resistance. KPC, NDM, VIM, IMP, and OXA-48-like are the most prevalent carbapenemases. Identification of CROs is based on the resistance phenotype or requires molecular assays, which are not widely available. A lateral flow assay (LFA) has been developed to enable rapid identification of carbapenemase production in cultured bacteria. Methods A total of 87 isolates characterised by Whole Genome Sequence (WGS) were tested. Five ATCC strains were used for quality control. LFA was performed according to the kit literature, and the results were compared with those by WGS. The assay was assessed for its sensitivity and specificity for the detection of five major carbapenemases. Results A total of 87 isolates of Enterobacterales and Pseudomonas aeruginosa, characterised by WGS, were tested. Of these, 52 were positive for the big five carbapenemases (IMP, VIM, KPC, NDM, and OXA-48-like), and 35 were negative. ATCC strains were run for quality control with each batch of tests. Overall sensitivity of the assay was 98.07 per cent (51/52), with no false positives, having 100 per cent specificity (35/35). The assay correctly detected strains producing KPC, OXA-48-like, VIM, and IMP, being 100 per cent sensitive (n=33/33) when compared with WGS results; whereas, it showed delayed positivity (>15 min) to identify one strain producing NDM-1 (thus considered false negative), accounting to sensitivity of 92.3 per cent (n=12/13) for detection of NDM. It correctly identified six strains simultaneously producing OXA-48-like and NDM, and one strain producing NDM-1 and KPC. Interpretation & conclusions The assay, being robust and cost-effective, with a short turn-around-time, will prove to be a great addition to the diagnostic armamentarium, helping in implementing antimicrobial stewardship and preventing AMR.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.